Nanoparticle HIV vaccine shows potential in trial
Positive first-in-human trial results have highlighted potential of a nanoparticle vaccine towards broadly neutralising against HIV.
Stay updated with breaking news from William Schief. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive first-in-human trial results have highlighted potential of a nanoparticle vaccine towards broadly neutralising against HIV.
Experimental shot activates rare immune cells that may help protect against quickly changing virus, study finds.
Experimental vaccine aims to train B cells to produce broadly neutralizing antibodies that target HIV.
According to findings from a first-in-human clinical trial, while researchers had previously struggled to develop an effective vaccine against HIV, a fresh vaccine design technique being followed by researchers shows new promise.
This HIV vaccine candidate recently completed its Phase 1 clinical trial and has shown promising results so far.